Blue Owl Capital Holdings’s ADC Therapeutics ADCT Stock Holding History

Blue Owl Capital Holdings’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.59M	Hold	733,568	–	–	0.7%	28
2025 Q4	$2.93M	Hold	733,568	–	–	0.91%	30
2025 Q3	$2.93M	Hold	733,568	–	–	0.91%	28
2025 Q2	$1.97M	Hold	733,568	–	–	0.63%	30
2025 Q1	$1.03M	Hold	733,568	–	–	0.33%	34
2024 Q4	$1.46M	Hold	733,568	–	–	0.34%	33
2024 Q3	$2.31M	Hold	733,568	–	–	0.45%	37
2024 Q2	$2.32M	Hold	733,568	–	–	0.64%	27
2024 Q1	$3.29M	Hold	733,568	–	–	0.66%	29
2023 Q4	$1.22M	Hold	733,568	–	–	0.29%	31
2023 Q3	$654K	Hold	733,568	–	–	0.51%	10
2023 Q2	$1.58M	Hold	733,568	–	–	0.97%	11
2023 Q1	$1.43M	Hold	733,568	–	–	0.92%	11
2022 Q4	$2.82M	Hold	733,568	–	–	1.2%	15
2022 Q3	$3.54M	Buy	+733,568	New	+$5.31M	1.53%	15

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Blue Owl Capital Holdings's ADCT Position: Q1 2026 in Review

Blue Owl Capital Holdings held its ADC Therapeutics (ADCT) position steady in Q1 2026 at 733,568 shares worth $2.59M. The position accounts for 0.7% of the portfolio, ranked #28.

Blue Owl Capital Holdings first reported a position in ADCT in Q3 2022 and has held it in 15 quarters since. The position peaked at $3.54M in Q3 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Blue Owl Capital Holdings held 733,568 shares of ADC Therapeutics worth $2.59M as of Q1 2026.
Blue Owl Capital Holdings left its ADC Therapeutics share count unchanged in Q1 2026.
ADC Therapeutics made up 0.7% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #28 holding.
Blue Owl Capital Holdings first reported a position in ADC Therapeutics in Q3 2022 and has held it in 15 quarters since.
Blue Owl Capital Holdings's ADC Therapeutics position peaked at $3.54M in Q3 2022.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.